A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

Investigator: Olga Waln, MD

Study Coordinator: Yvonne Subhan

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT04658186

Phone: 346.238.9068

Protocol Number: PRO00029918


The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.
More to Explore